연구성과로 돌아가기
2023 연구성과별 연구자 정보 (1343 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Chen, M. | Chen, M | 3 | Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Cheng, A-L | Cheng, AL | 4 | Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Cheng, A-L | Cheng, AL | 4 | Natl Taiwan Univ Hosp, Taipei, Taiwan | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Kaseb, A. | Kaseb, A | 5 | MD Anderson Canc Ctr, Houston, TX USA | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Kudo, M. | Kudo, M | 6 | Kindai Univ, Osaka, Japan | AAA-9744-2019 | Kudo, Masatoshi | ||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Lee, H. C. | Lee, HC | 7 | Univ Ulsan, Asan Med Ctr, Seoul, South Korea | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Yopp, A. | Yopp, A | 8 | UT Southwestern Med Ctr, Dallas, TX USA | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Zhou, J. | Zhou, J | 9 | Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Wang, L. | Wang, L | 10 | Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Wen, X. | Wen, X | 11 | 1st Hosp Jilin Univ, Jilin, Jilin, Peoples R China | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Heo, J. | Heo, J | 12 | Pusan Natl Univ, Coll Med, Busan, South Korea | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Heo, J. | Heo, J | 12 | Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Tak, W-Y | Tak, WY | 13 | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Nakamura, S. | Nakamura, S | 14 | Himeji Red Cross Hosp, Himeji, Hyogo, Japan | ||||||
| IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation | Numata, K. | Numata, K | 15 | Yokohama City Univ, Med Ctr, Yokohama, Kanagawa, Japan |
페이지 이동: